0001493152-23-020081.txt : 20230605 0001493152-23-020081.hdr.sgml : 20230605 20230605080532 ACCESSION NUMBER: 0001493152-23-020081 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230605 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230605 DATE AS OF CHANGE: 20230605 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Dare Bioscience, Inc. CENTRAL INDEX KEY: 0001401914 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 204139823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36395 FILM NUMBER: 23991278 BUSINESS ADDRESS: STREET 1: 3655 NOBEL DRIVE STREET 2: SUITE 260 CITY: SAN DIEGO STATE: CA ZIP: 92122 BUSINESS PHONE: 858-926-7655 MAIL ADDRESS: STREET 1: 3655 NOBEL DRIVE STREET 2: SUITE 260 CITY: SAN DIEGO STATE: CA ZIP: 92122 FORMER COMPANY: FORMER CONFORMED NAME: Cerulean Pharma Inc. DATE OF NAME CHANGE: 20090714 FORMER COMPANY: FORMER CONFORMED NAME: Tempo Pharmaceuticals Inc DATE OF NAME CHANGE: 20070604 8-K 1 form8-k.htm
0001401914 false Dare Bioscience, Inc. 0001401914 2023-06-05 2023-06-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 5, 2023

 

DARÉ BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-36395   20-4139823

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

3655 Nobel Drive, Suite 260

San Diego, CA 92122

(Address of Principal Executive Offices and Zip Code)

 

Registrant’s telephone number, including area code: (858) 926-7655

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock   DARE   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 7.01 Regulation FD Disclosure.

 

On June 5, 2023, Daré Bioscience, Inc. (Daré), issued a press release reporting topline results from the clinical trial discussed in Item 8.01 below. A copy of the press release is furnished as Exhibit 99.1 to this report.

 

The information under this Item 7.01 and in Exhibit 99.1 is being furnished and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such a filing.

 

Item 8.01 Other Events.

 

Topline results from exploratory Phase 2b RESPOND clinical trial of Sildenafil Cream, 3.6%

 

On June 5, 2023, Daré announced topline results from its exploratory Phase 2b RESPOND clinical trial of Sildenafil Cream, 3.6% (Sildenafil Cream) in patients with female sexual arousal disorder (FSAD). The exploratory Phase 2b RESPOND study was a multi-center, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of Sildenafil Cream in premenopausal patients with FSAD. The study was a first of its kind Phase 2b clinical study that includes patient reported outcome (PRO) instruments to screen eligible women with FSAD and included two co-primary endpoints, a secondary endpoint, and a number of exploratory endpoints to measure, among other things, improvement in localized genital sensations of arousal, reduction in the distress that women experience with FSAD and satisfactory sexual events.

 

There are no treatments approved by the U.S. Food and Drug Administration (FDA) for FSAD and thus there are no efficacy endpoints that have been previously validated in a Phase 3 pivotal study for potential treatments for FSAD. The exploratory Phase 2b RESPOND study also served as a validation study of exploratory endpoints that could be candidate endpoints in a Phase 3 study of Sildenafil Cream. The FDA requested that any PROs for use in the assessment of efficacy in a Phase 3 study be adequately validated. Part of that validation of the PROs includes exit interviews performed as part of the exploratory Phase 2b RESPOND study to better understand qualitatively what constitutes a meaningful change to the subjects. These qualitative assessments of meaningful change were utilized to determine which endpoints achieved meaningful improvement in the Sildenafil Cream group. Additional psychometric analyses using the exploratory Phase 2b RESPOND study dataset is planned to further refine and validate the measures to inform the most appropriate endpoints for use in a Phase 3 pivotal study of Sildenafil Cream.

 

The exploratory Phase 2b RESPOND study began with 99 subjects in the Sildenafil Cream intent to treat population and 93 subjects in the placebo intent to treat population, with 70 subjects in the Sildenafil Cream intent to treat population and 60 subjects in the placebo intent to treat population completing the study, and therefore was underpowered to assess statistical significance, although certain endpoints achieved statistical significance. During the study, participants used Sildenafil Cream and a placebo cream in their home setting and documented their experience using PRO instruments. The study evaluated Sildenafil Cream compared to placebo cream over 12 weeks of dosing following both a non-drug and placebo run-in period.

 

Daré intends to review the data with the FDA, including discussing the data from assessments as early as the 4- and 8-week mark after randomization, and to continue the development of Sildenafil Cream, including advancing Sildenafil Cream into a Phase 3 pivotal study for the treatment of FSAD. Following clinical development, Daré intends to leverage the existing safety and efficacy data on the active ingredient in Sildenafil Cream to utilize the FDA’s 505(b)(2) pathway to obtain marketing approval of Sildenafil Cream in the U.S.

 

Summary of Topline Data

 

A co-primary endpoint of the Phase 2b RESPOND study was to evaluate the efficacy of Sildenafil Cream compared to placebo as measured by change from baseline to the end of the study in the Arousal-Sensation Domain of the 28-item Sexual Function Questionnaire (SFQ28). The endpoint did not achieve statistical significance. However, the change at the end of the study in the group treated with Sildenafil Cream was consistent with how women reported meaningful improvement in an exit interview at the end of the study.

 

The other co-primary endpoint was to evaluate the efficacy of Sildenafil Cream compared to placebo as measured by change from baseline to the end of the study in the score for feeling concerned by difficulties with sexual arousal. The change was assessed using the previously validated Female Sexual Distress Scale – Desire, Arousal and Orgasm (FSDS-DAO) Survey. This assessment did not differentiate Sildenafil Cream from placebo.

 

The secondary endpoint was to evaluate the efficacy of Sildenafil Cream compared to placebo as measured by change from baseline to the end of the study in the number of satisfactory sexual events based on the subjects’ response to a question answered and recorded via electronic diary within 24 hours after each sexual event. The endpoint was selected because it can serve as a primary endpoint in a Phase 3 study based on the FDA draft 2016 guidance document for female sexual dysfunction. When measured at the 4- and 8-week mark after randomization, subjects treated with Sildenafil Cream had a higher proportion of satisfying sexual events during the prior month (68.6% and 74.1% at the 4- and 8-week mark, respectively) compared to those treated with placebo (47.9% and 67.9% at the 4- and 8-week mark, respectively) (week 4 P value = 0.04).

 

-2-
 

 

The exploratory endpoints (selected based on the content validity study previously conducted by SST and Daré) included endpoints related to genital arousal, genital blood flow, lubrication, orgasm, concerns about difficulties with sexual arousal, and other assessments including questions regarding satisfying sexual events. The exploratory endpoints were assessed at multiple periods over the course of the study via electronic diary.

 

●An exploratory endpoint regarding concerns about difficulties with sexual arousal differentiated Sildenafil Cream versus placebo. Specifically, when asked about their overall impression of change regarding their concerns about difficulties with sexual arousal, women treated with Sildenafil Cream were more likely to report an overall improvement. Based on responses to the question at the 4-, 8- and 12-week mark after randomization, 44% to 49% of the subjects treated with Sildenafil Cream reported an overall improvement compared to 37% to 44% of the subjects treated with placebo (P value < 0.01).

 

●Exploratory endpoints related to arousal lubrication and achievement and pleasure of orgasm also demonstrated important differences between the subjects treated with Sildenafil Cream compared to placebo as measured by change from baseline to the 8-week mark after randomization, at P value = 0.059 and P value = 0.066, respectively (trending toward significance despite the small number of subjects in each group, n=73 in the Sildenafil Cream intent to treat group and n=64 in the placebo intent to treat group for these assessments).

 

●48.7% of the subjects treated with Sildenafil Cream reported an increase in their overall satisfaction with sexual activity measured at the end of the study, compared to 42.6% of the subjects treated with placebo.

 

Summary of Cited Top Line Data

 

The exploratory Phase 2b RESPOND study was underpowered to assess statistical significance, although statistical significance was achieved on certain assessments. The following table sets forth certain data regarding the co-primary endpoints, the secondary endpoint, and certain exploratory endpoints:

 

Objective/Endpoint   Measured At   Sildenafil
Cream, N(1)		   Placebo, N(1)   P value
Co-Primary: SFQ28 Arousal Sensation Domain   End of study (week 12)   70   60   >0.05
Co-Primary: FSDS-DAO Survey (Q14 only (Concerned by difficulties with sexual arousal))   End of study (week 12)   70   60   >0.05
Secondary: Proportion of Satisfactory Sexual Events per Month during Double Blind Treatment Period  

Week 4

 

Week 8

 

Week 12

  

78

 

73

 

71

  

68

 

64

 

61

  

0.04

 

>0.05

 

>0.05

Exploratory: Arousal Lubrication PROs   Week 8   73   64   0.059
Exploratory: Orgasm PROs   Week 8   73   64   0.066
Exploratory: Regarding Concern for FSAD Symptoms(2)   Weeks 4 - 12   78   68   <0.01
Exploratory: Regarding Satisfactory Sexual Activity(2)   Weeks 4 - 12   78   68   <0.01

 

(1) The numbers in this column represent the number of subjects included in the assessment at the indicated time point.
 
(2) This exploratory endpoint was measured periodically beginning at week 4 after randomization through the end of the study.

 

Safety

 

Sildenafil Cream was generally safe and well-tolerated. There were no treatment related serious adverse events and the majority of treatment related adverse events were mild in severity.

 

-3-
 

 

Other Matters

 

Daré currently continues to anticipate the following upcoming milestone events for its portfolio:

 

●2Q-2023: First commercial sale in the United States of XACIATO™ (clindamycin phosphate) vaginal gel, 2%, an FDA-approved product indicated for the treatment of bacterial vaginosis in females 12 years and older;

 

●Mid-2023: Initiation of patient recruitment for the planned pivotal Phase 3 clinical study of Ovaprene®, an investigational hormone-free, monthly intravaginal contraceptive; and

 

●2023: Announcement of topline results from the ongoing Phase 1 clinical study of DARE-PDM1, an investigational proprietary hydrogel formulation of diclofenac, a nonsteroidal anti-inflammatory drug, being developed as a vaginally-administered treatment for primary dysmenorrhea.

 

Cautionary Statement Regarding Forward-Looking Statements

 

Daré cautions you that all statements, other than statements of historical facts, contained in this report, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “objective,” or the negative version of these words and similar expressions. In this report, forward-looking statements include, but are not limited to, statements relating to Sildenafil Cream’s potential as a safe and effective therapy for FSAD, Daré’s plans for continued clinical development of Sildenafil Cream, the anticipated regulatory pathway for Sildenafil Cream, the potential for Sildenafil Cream to be the first FDA-approved treatment for FSAD, the potential market opportunity for Sildenafil Cream, plans and expectations with respect to Daré’s product candidates, including anticipated timing for the first commercial sale of XACIATO, for commencement and conduct of clinical trials and for announcement of topline results. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Daré’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this report, including, without limitation, risk and uncertainties related to: the risk that topline results from a clinical trial, including the Phase 2b RESPOND study, are based on Daré’s preliminary analysis of key efficacy and safety data and, following a comprehensive review of the study data, topline results may not accurately reflect the complete results from the study and the differences between topline results and complete results may be significant and may adversely impact the continued clinical development of the investigational product, including anticipated time and expense of continued development; the risk that data from the Phase 2b RESPOND study, which assessed multiple patient reported outcomes at 4, 8 and 12 weeks after randomization, may not be predictive of results of any future clinical study that assesses safety and efficacy of Sildenafil Cream at time points beyond 12 weeks after randomization, and the double-blind dosing period the FDA may require for a pivotal Phase 3 study of Sildenafil Cream is unknown at this time; the risk that the FDA, other regulatory authorities, members of the scientific or medical communities or investors may not accept or agree with Daré’s interpretation of or conclusions regarding the study data; Daré’s ability to raise additional capital when and as needed to advance its product candidates, execute its business strategy and continue as a going concern; the risk that positive findings in early clinical and/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate; the risk that development of a product candidate requires more clinical or nonclinical studies than Daré anticipates; Daré’s ability to develop, obtain FDA or foreign regulatory approval for, and commercialize its product candidates and to do so on communicated timelines; failure or delay in starting, conducting and completing clinical trials of a product candidate; Daré’s ability to design and conduct successful clinical trials, to enroll a sufficient number of patients, to meet established clinical endpoints, to avoid undesirable side effects and other safety concerns, and to demonstrate sufficient safety and efficacy of its product candidates; Daré’s dependence on third parties to conduct clinical trials and manufacture and supply clinical trial material and commercial product; the loss of, or inability to attract, key personnel; the effects of the COVID-19 pandemic, macroeconomic conditions and geopolitical events on Daré’s operations, financial results and condition, and ability to achieve current plans and objectives, including the potential impact of the pandemic on Daré’s ability to timely commence, enroll, conduct and report results of its clinical trials and on the ability of third parties on which Daré relies to assist in the conduct of its business to fulfill their contractual obligations to Daré; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; the risk that developments by competitors make Daré’s product or product candidates less competitive or obsolete; difficulties establishing and sustaining relationships with development and/or commercial collaborators; failure of Daré’s product or product candidates, if approved, to gain market acceptance or obtain adequate coverage or reimbursement from third-party payers; Daré’s ability to retain its licensed rights to develop and commercialize a product or product candidate; Daré’s ability to satisfy the monetary obligations and other requirements in connection with its exclusive, in-license agreements covering the critical patents and related intellectual property related to its product and product candidates; Daré’s ability to adequately protect or enforce its, or its licensor’s, intellectual property rights; the lack of patent protection for the active ingredients in certain of Daré’s product candidates which could expose its products to competition from other formulations using the same active ingredients; product liability claims; governmental investigations or actions relating to Daré’s product or product candidates or the business activities of Daré, its commercial collaborators or other third parties on which Daré relies; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; cyber attacks, security breaches or similar events that compromise Daré’s technology systems or those of third parties on which it relies and/or significantly disrupt Daré’s business; and disputes or other developments concerning Daré’s intellectual property rights. Daré’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Daré’s risks and uncertainties, you are encouraged to review its documents filed with the SEC including Daré’s recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Daré undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press release issued on June 5, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

-4-
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

DARÉ BIOSCIENCE, INC.

   
Dated: June 5, 2023 By: /s/ Sabrina Martucci Johnson
  Name: Sabrina Martucci Johnson
  Title: President and Chief Executive Officer

 

-5-

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

Daré Bioscience Announces Positive Topline Data from the Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder

 

Sildenafil Cream-treated patients showed meaningful improvement in the co-primary endpoint assessment that evaluated change from baseline in the Arousal-Sensation Domain of the Sexual Function Questionnaire

 

Sildenafil Cream-treated patients also showed improvements in the secondary endpoint and pre-specified exploratory endpoints that evaluated sexual satisfaction, arousal lubrication, and achievement and pleasure of orgasm

 

Data support continued development of Sildenafil Cream and selection of proposed primary endpoint assessments for a Phase 3 study

 

Sildenafil Cream has the potential to be the first FDA-approved treatment for female sexual arousal disorder

 

SAN DIEGO, June 5, 2023 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and its collaborator Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced positive topline data from the exploratory Phase 2b RESPOND study evaluating topical Sildenafil Cream, 3.6% (Sildenafil Cream) as a treatment for female sexual arousal disorder (FSAD). The exploratory study was designed to test the sensitivity of several patient reported outcome (PRO) efficacy endpoints and their ability to determine a treatment effect of Sildenafil Cream compared to placebo to inform the ongoing development of Sildenafil Cream. The study also served as a validation study of exploratory endpoints that could be candidate endpoints in a Phase 3 study of Sildenafil Cream. Although the exploratory study was underpowered to assess statistical significance, certain endpoints achieved statistical significance.

 

FSAD is the inability to reach or maintain a sufficient physical response to sexual stimulation and, of the various types of female sexual dysfunction disorders, FSAD is most analogous to erectile dysfunction (ED) in men. Sildenafil, a phosphodiesterase-5 (PDE-5) inhibitor, is the active ingredient in a tablet for oral administration currently marketed under the brand name Viagra® for the treatment of ED in men. Sildenafil Cream is an investigational proprietary topical cream formulation of sildenafil specifically designed to increase blood flow to the genital tissue in women. If development is successful, Sildenafil Cream has the potential to be the first FDA-approved treatment for FSAD. Market research suggests that 16% of women in the U.S. ages 21 to 60, or approximately 10 million women, are distressed from experiencing symptoms associated with FSAD, including lack of or low sexual arousal, and are actively seeking solutions to improve their condition. In comparison, the prevalence of complete ED in men is estimated to be about 5% of men at age 40, increasing to about 15% at age 70.

 

“We are very pleased with the topline data from the Phase 2b RESPOND study. Although the study was underpowered to assess statistical significance, we saw statistically significant results for certain of the endpoints, and the data indicate that, as compared to placebo, Sildenafil Cream had a therapeutic effect based on several PROs,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience. “Because there are currently no FDA-approved treatments for FSAD, there are no efficacy endpoints that have been previously approved for use in a Phase 3 pivotal study for potential treatment for FSAD – but with the data from the Phase 2b RESPOND study we believe certain of the primary, secondary, and exploratory endpoints could be candidate endpoints in a Phase 3 study of Sildenafil Cream. Having now completed this pioneering work in the field of FSAD, we look forward to reviewing the data with the FDA, including discussing the data from assessments as early as the 4- and 8-week mark after randomization, and continuing the development of Sildenafil Cream, including our objective of initiating the first ever Phase 3 pivotal study for the treatment of FSAD. Following clinical development, Daré intends to leverage the existing safety and efficacy data on the active ingredient in Sildenafil Cream to utilize the FDA’s 505(b)(2) pathway to obtain marketing approval of Sildenafil Cream in the U.S.”

 

 
 

 

“The FDA has not approved any pharmacologic options for FSAD, a condition which significantly compromises a woman’s ability to have a pleasurable sexual experience,” commented Dr. Sheryl Kingsberg, Division Chief of Behavioral Medicine, Department of OBGYN, University Hospitals Cleveland Medical Center, Ohio, and Past President of The International Society for the Study of Women’s Sexual Health, as well as co-editor of the Textbook of Female Sexual Function and Dysfunction: Diagnosis and Treatment. “Based on the topline data from the Phase 2b RESPOND study I am very excited about the potential for this topical Sildenafil Cream to address this critical unmet need in women’s sexual health. Leveraging the known therapeutic benefit of the active ingredient in Viagra®, sildenafil, in a cream formulation to stimulate increased blood flow to the genital tissue, Sildenafil Cream may offer women a safe, effective and ‘on demand’ solution to difficulties with sexual arousal allowing for a more intense and enjoyable sexual experience.”

 

Unlike the oral formulations of PDE-5 inhibitors, Sildenafil Cream is designed to be applied locally to the vulvar-vaginal tissue prior to sexual activity to facilitate vasodilation and increase blood flow directly to the genital tissue to improve the physical arousal response to address the lack of those genital arousal sensations commonly associated with FSAD. Increasing blood flow to the genital tissue, as Sildenafil Cream is designed to do, has the potential to improve genital arousal response and overall sexual experience for women. This is similar to the way ED medications work in men by directing blood flow to the genitals when taken prior to sexual activity.

 

“The topline data from the Phase 2b RESPOND study represent an important milestone in the field of female sexual dysfunction,” said Dr. Andrew Goldstein, Medical Advisor of Daré Bioscience and Past President of The International Society for the Study of Women’s Sexual Health, as well as co-editor of the Textbook of Female Sexual Function and Dysfunction: Diagnosis and Treatment. “It is exciting to be working at the cutting edge of research focused on women’s sexual health and to advance a potential first-in-category treatment option for women suffering with FSAD.”

 

“It is encouraging to see sponsors such as Daré and SST developing endpoints that will foster approval of new medicines for women in FSAD. The previously completed content validation study and the exit interviews completed as part of the Phase 2b RESPOND study are significant steps to gaining regulatory approval of endpoints in this area. I look forward to continuing our collaboration by using the Phase 2b RESPOND study data to conduct psychometric analyses to further refine the measures and resulting endpoints for use in a Phase 3 pivotal study,” said Tara Symonds, Ph.D., Managing Director, UK, and Chief Scientific Officer at Clinical Outcomes Solutions, who is an advisor to Daré and SST and has extensive expertise in the development and validation of PROs for sexual health clinical trials, including establishing and leading Pfizer’s PRO Center of Excellence earlier in her career.

 

Daré plans to submit data from the Phase 2b RESPOND clinical study of Sildenafil Cream for publication in a peer-reviewed journal.

 

About the Exploratory Phase 2b RESPOND Study

 

Study Design

 

The exploratory Phase 2b RESPOND study was a multi-center, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of Sildenafil Cream in premenopausal patients with FSAD. The study was a first of its kind Phase 2b clinical study that includes PRO instruments to screen eligible women with FSAD and included two co-primary endpoints, a secondary endpoint, and a number of exploratory endpoints to measure, among other things, improvement in localized genital sensations of arousal, reduction in the distress that women experience with FSAD and satisfactory sexual events. There are no FDA-approved treatments for FSAD and thus there are no efficacy endpoints that have been previously validated in a Phase 3 pivotal study for potential treatments for FSAD.

 

 
 

 

The FDA requested that any PROs for use in the assessment of efficacy in a Phase 3 study be adequately validated. Part of that validation of the PROs includes exit interviews performed as part of the Phase 2b RESPOND study to better understand qualitatively what constitutes a meaningful change to the subjects. These qualitative assessments of meaningful change were utilized to determine which endpoints achieved meaningful improvement in the Sildenafil Cream group. Additional psychometric analyses using the Phase 2b RESPOND study dataset is planned to further refine and validate the measures to inform the most appropriate endpoints for use in a Phase 3 pivotal study.

 

The Phase 2b RESPOND study began with 99 subjects in the Sildenafil Cream intent to treat population and 93 subjects in the placebo intent to treat population, with 70 subjects in the Sildenafil Cream intent to treat population and 60 subjects in the placebo intent to treat population completing the study, and therefore was underpowered to assess statistical significance. During the study, participants used Sildenafil Cream and a placebo cream in their home setting and documented their experience using PRO instruments. The study evaluated Sildenafil Cream compared to placebo cream over 12 weeks of dosing following both a non-drug and placebo run-in period.

 

Study Efficacy Results and Safety

 

Summary of Topline Data

 

A co-primary endpoint of the Phase 2b RESPOND study was to evaluate the efficacy of Sildenafil Cream compared to placebo as measured by change from baseline to the end of the study in the Arousal-Sensation Domain of the 28-item Sexual Function Questionnaire (SFQ28). The endpoint did not achieve statistical significance. However, the change at the end of the study in the group treated with Sildenafil Cream was consistent with how women reported meaningful improvement in an exit interview at the end of the study.

 

The other co-primary endpoint was to evaluate the efficacy of Sildenafil Cream compared to placebo as measured by change from baseline to the end of the study in the score for feeling concerned by difficulties with sexual arousal. The change was assessed using the previously validated Female Sexual Distress Scale – Desire, Arousal and Orgasm (FSDS-DAO) Survey. This assessment did not differentiate Sildenafil Cream from placebo.

 

The secondary endpoint of the study was to evaluate the efficacy of Sildenafil Cream compared to placebo as measured by change from baseline to the end of the study in the number of satisfactory sexual events based on the subjects’ response to a question answered and recorded via electronic diary within 24 hours after each sexual event. The endpoint was selected because it can serve as a primary endpoint in a Phase 3 study based on the FDA draft 2016 guidance document for female sexual dysfunction. When measured at the 4- and 8-week mark after randomization, subjects treated with Sildenafil Cream had a higher proportion of satisfying sexual events during the prior month (68.6% and 74.1% at the 4- and 8-week mark, respectively) compared to those treated with placebo (47.9% and 67.9% at the 4- and 8-week mark, respectively) (week 4 P value = 0.04).

 

 
 

 

The exploratory endpoints (selected based on the Content Validity study conducted by SST and Daré) included endpoints related to genital arousal, genital blood flow, lubrication, orgasm, concerns about difficulties with sexual arousal, and other assessments including questions regarding satisfying sexual events. The exploratory endpoints were assessed at multiple periods over the course of the study via electronic diary.

 

●An exploratory endpoint regarding concerns about difficulties with sexual arousal differentiated Sildenafil Cream versus placebo. Specifically, when asked about their overall impression of change regarding their concerns about difficulties with sexual arousal, women treated with Sildenafil Cream were more likely to report an overall improvement. Based on responses to the question at the 4-, 8- and 12-week mark after randomization, 44% to 49% of the subjects treated with Sildenafil Cream reported an overall improvement compared to 37% to 44% of the subjects treated with placebo (P value < 0.01).

 

●Exploratory endpoints related to arousal lubrication and achievement and pleasure of orgasm also demonstrated important differences between the subjects treated with Sildenafil Cream compared to placebo as measured by change from baseline to the 8-week mark after randomization, at P value = 0.059 and P value = 0.066, respectively (trending toward significance despite the small number of subjects in each group, n=73 in the Sildenafil Cream intent to treat group and n=64 in the placebo intent to treat group for these assessments).

 

●48.7% of the subjects treated with Sildenafil Cream reported an increase in their overall satisfaction with sexual activity measured at the end of the study, compared to 42.6% of the subjects treated with placebo.

 

Summary of Cited Top Line Data

 

The exploratory Phase 2b RESPOND study was underpowered to assess statistical significance, although statistical significance was achieved on certain assessments. The following table sets forth certain data regarding the co-primary endpoints, the secondary endpoint, and certain exploratory endpoints:

 

Objective/Endpoint   Measured At   Sildenafil
Cream, N(1)		   Placebo, N(1)   P value
Co-Primary: SFQ28 Arousal Sensation Domain   End of study (week 12)   70   60   >0.05
Co-Primary: FSDS-DAO Survey (Q14 only (Concerned by difficulties with sexual arousal))   End of study (week 12)   70   60   >0.05
Secondary: Proportion of Satisfactory Sexual Events per Month during Double Blind Treatment Period  

Week 4

 

Week 8

 

Week 12

  

78

 

73

 

71

 

68

 

64

 

61

 

0.04

 

>0.05

 

>0.05

Exploratory: Arousal Lubrication PROs   Week 8   73   64   0.059
Exploratory: Orgasm PROs   Week 8   73   64   0.066
Exploratory: Regarding Concern for FSAD Symptoms(2)   Weeks 4 - 12   78   68   <0.01
Exploratory: Regarding Satisfactory Sexual Activity(2)   Weeks 4 - 12   78   68   <0.01

 

(1) The numbers in this column represent the number of subjects included in the assessment at the indicated time point.
 
(2) This exploratory endpoint was measured periodically beginning at week 4 after randomization through the end of the study.

 

 
 

 

Safety

 

Sildenafil Cream was generally safe and well-tolerated. There were no treatment related serious adverse events and the majority of treatment related adverse events were mild in severity.

 

About FSAD and Sildenafil Cream, 3.6%

 

FSAD is distinct from hypoactive sexual desire disorder (HSDD) in women, which is characterized primarily by a lack of sexual desire. FSAD is a condition characterized primarily by a persistent or recurrent inability to attain or maintain sufficient genital arousal (an adequate lubrication-swelling response) during sexual activity, frequently resulting in distress or interpersonal difficulty. As with ED in men, FSAD is associated with insufficient blood flow to the genitalia.

 

Market research suggests that 16% of women in the U.S. ages 21 to 60, or approximately 10 million women, are distressed from experiencing symptoms associated with FSAD, including lack of or low sexual arousal, and are actively seeking solutions to improve their condition. In comparison, the prevalence of complete ED in men is estimated to be about 5% of men at age 40, increasing to about 15% at age 70. Daré believes the potential market opportunity for an FDA-approved treatment for FSAD is comparable in size to the market for FDA-approved treatments for ED in men.

 

Sildenafil Cream, 3.6% is an investigational proprietary cream formulation of sildenafil, a PDE-5 inhibitor, designed for topical administration to the vulvar-vaginal tissue to increase genital blood flow and provide improvements in the female genital arousal response, while avoiding systemic side effects observed with oral formulations of sildenafil. Sildenafil Cream has been previously evaluated in Phase 1 and Phase 2a clinical studies. In a Phase 1 clinical study in 20 healthy post-menopausal women, topical Sildenafil Cream was safe and well tolerated at clinically relevant doses, and study subjects reported favorable product characteristics: easy to use and readily absorbed. In a Phase 2a study in women with FSAD (15 pre-menopausal and 16 post-menopausal), Sildenafil Cream increased measurable blood flow to the genital tissue compared to placebo cream. Further, data from a thermography study in six healthy women demonstrated significantly greater increases in genital temperature after administration of Sildenafil Cream compared to placebo cream, indicating a positive impact on genital blood flow during the 30-minute testing session, with statistical separation from placebo within the first 15 minutes of dosing.

 

About Daré Bioscience

 

Daré Bioscience is a biopharmaceutical company committed to advancing innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that prioritize women’s health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, vaginal health, reproductive health, menopause, sexual health and fertility.

 

Daré’s first FDA-approved product, XACIATO™ (clindamycin phosphate) vaginal gel, 2% is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. XACIATO is a clear, colorless, viscous gel, to be administered once intravaginally as a single dose. Daré’s portfolio also includes potential first-in-category candidates in clinical development: Ovaprene®, a novel, hormone-free monthly intravaginal contraceptive whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra®; and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy. To learn more about XACIATO, Daré’s full portfolio of women’s health product candidates, and Daré’s mission to deliver differentiated therapies for women, please visit www.darebioscience.com.

 

Daré may announce material information about its finances, product and product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its finances, product and product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts in the Investors section of its website and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted in the Investors section of Daré’s website.

 

 
 

 

Forward-Looking Statements

 

Daré cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “objective,” or the negative version of these words and similar expressions. In this press release, forward-looking statements include, but are not limited to, statements relating to Sildenafil Cream’s potential as a safe and effective therapy for FSAD, Daré’s plans for continued clinical development of Sildenafil Cream, the anticipated regulatory pathway for Sildenafil Cream, the potential for Sildenafil Cream to be the first FDA-approved treatment for FSAD, and the potential market opportunity for Sildenafil Cream. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Daré’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risk and uncertainties related to: the risk that topline results from a clinical trial, including the Phase 2b RESPOND study, are based on Daré’s preliminary analysis of key efficacy and safety data and, following a comprehensive review of the study data, topline results may not accurately reflect the complete results from the study and the differences between topline results and complete results may be significant and may adversely impact the continued clinical development of the investigational product, including anticipated time and expense of continued development; the risk that data from the Phase 2b RESPOND study, which assessed multiple patient reported outcomes at 4, 8 and 12 weeks after randomization, may not be predictive of results of any future clinical study that assesses safety and efficacy of Sildenafil Cream at time points beyond 12 weeks after randomization, and the double-blind dosing period the FDA may require for a pivotal Phase 3 study of Sildenafil Cream is unknown at this time; the risk that the FDA, other regulatory authorities, members of the scientific or medical communities or investors may not accept or agree with Daré’s interpretation of or conclusions regarding the study data; Daré’s ability to raise additional capital when and as needed to advance its product candidates, execute its business strategy and continue as a going concern; the risk that positive findings in early clinical and/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate; the risk that development of a product candidate requires more clinical or nonclinical studies than Daré anticipates; Daré’s ability to develop, obtain FDA or foreign regulatory approval for, and commercialize its product candidates and to do so on communicated timelines; failure or delay in starting, conducting and completing clinical trials of a product candidate; Daré’s ability to design and conduct successful clinical trials, to enroll a sufficient number of patients, to meet established clinical endpoints, to avoid undesirable side effects and other safety concerns, and to demonstrate sufficient safety and efficacy of its product candidates; Daré’s dependence on third parties to conduct clinical trials and manufacture and supply clinical trial material and commercial product; the loss of, or inability to attract, key personnel; the effects of the COVID-19 pandemic, macroeconomic conditions and geopolitical events on Daré’s operations, financial results and condition, and ability to achieve current plans and objectives, including the potential impact of the pandemic on Daré’s ability to timely commence, enroll, conduct and report results of its clinical trials and on the ability of third parties on which Daré relies to assist in the conduct of its business to fulfill their contractual obligations to Daré; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; the risk that developments by competitors make Daré’s product or product candidates less competitive or obsolete; difficulties establishing and sustaining relationships with development and/or commercial collaborators; failure of Daré’s product or product candidates, if approved, to gain market acceptance or obtain adequate coverage or reimbursement from third-party payers; Daré’s ability to retain its licensed rights to develop and commercialize a product or product candidate; Daré’s ability to satisfy the monetary obligations and other requirements in connection with its exclusive, in-license agreements covering the critical patents and related intellectual property related to its product and product candidates; Daré’s ability to adequately protect or enforce its, or its licensor’s, intellectual property rights; the lack of patent protection for the active ingredients in certain of Daré’s product candidates which could expose its products to competition from other formulations using the same active ingredients; product liability claims; governmental investigations or actions relating to Daré’s product or product candidates or the business activities of Daré, its commercial collaborators or other third parties on which Daré relies; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; cyber attacks, security breaches or similar events that compromise Daré’s technology systems or those of third parties on which it relies and/or significantly disrupt Daré’s business; and disputes or other developments concerning Daré’s intellectual property rights. Daré’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Daré’s risks and uncertainties, you are encouraged to review its documents filed with the SEC including Daré’s recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Daré undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

 

Contacts:

 

Investors on behalf of Daré Bioscience, Inc.:
Lee Roth
Burns McClellan
lroth@burnsmc.com
646.930.4406

 

OR

 

Media on behalf of Daré Bioscience, Inc.:
Jake Robison
Evoke Canale
jake.robison@evokegroup.com
619.849.5383

 

Source: Daré Bioscience, Inc.

 

 

 EX-101.SCH 3 dare-20230605.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 dare-20230605_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 dare-20230605_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
Jun. 05, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 05, 2023
Entity File Number 001-36395
Entity Registrant Name Dare Bioscience, Inc.
Entity Central Index Key 0001401914
Entity Tax Identification Number 20-4139823
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 3655 Nobel Drive
Entity Address, Address Line Two Suite 260
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92122
City Area Code (858)
Local Phone Number 926-7655
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock
Trading Symbol DARE
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001401914 2023-06-05 2023-06-05 iso4217:USD shares iso4217:USD shares 0001401914 false Dare Bioscience, Inc. 8-K 2023-06-05 DE 001-36395 20-4139823 3655 Nobel Drive Suite 260 San Diego CA 92122 (858) 926-7655 false false false false Common stock DARE NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-8?20$3;8T.P6BP^0"X99K>]9!:G%C:^?VZH:TE[VE-S9 MNMQ=%A?BTX'HE'QY%V)N:I%FGJ:QJ,';>$<-!)U4Q-Z*0CZFL6&P9:P!Q+MT MFF6SU%L,9KD8M;:X1+_)UW,#ECQ ,ZE._<]'<')O$8T.,5 MRMQD)HDU75Z(\4I!K-L53,[E9C(,]L""Q1]ZUYG\M(?8,V(/'U:-Y&:6J6"% M'*7?Z/6M>CR#+@^H%7I")\!K*_#,U#88CIV,IDAO8O0]C.=0XIS_4R-5%1:P MIJ+U$&3HD<%U!D.LL8DF"=9#;E9T!N[RZ .;O\P>=0>6N=6RKV'5[+E&''\GN4/4$L#!!0 ( M *] Q58D'INBK0 /@! : >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E M;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_ M[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ M0=@S9)[NF:*'3^ 5!+ P04 M " "O0,5699!YDAD! #/ P $P %M#;VYT96YT7U1Y<&5S72YX;6RM MDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C> MO,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0 MP1-XJBA[E.O5,[1R;ZEXZ7D;3?!-FI6.5Z*U .EK >MKBRAE#VQH% M.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D M(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S6 M3AI_YHOA/UY_ 5!+ 0(4 Q0 ( *] Q58'04UB@0 +$ 0 M " 0 !D;V-0&UL4$L! A0#% @ KT#%5CSC M59WN *P( !$ ( !KP &1O8U!R;W!S+V-O&UL M4$L! A0#% @ KT#%5IE&PO=V]R:W-H965T&UL M4$L! A0#% @ KT#%5I^@&_"Q @ X@P T ( !DPP M 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! M A0#% @ KT#%5B0>FZ*M ^ $ !H ( !N!$ 'AL M+U]R96QS+W=O9(9 M 0 SP, !, ( !G1( %M#;VYT96YT7U1Y<&5S72YX;6Q0 52P4& D "0 ^ @ YQ, end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://darebioscience.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName - form8-k.htm 22 form8-k.htm dare-20230605.xsd dare-20230605_lab.xml dare-20230605_pre.xml ex99-1.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "dare-20230605_lab.xml" ] }, "presentationLink": { "local": [ "dare-20230605_pre.xml" ] }, "schema": { "local": [ "dare-20230605.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "DARE", "nsuri": "http://darebioscience.com/20230605", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-06-05to2023-06-05", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://darebioscience.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-06-05to2023-06-05", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://darebioscience.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001493152-23-020081-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-020081-xbrl.zip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